Role of antibody-based therapy in indolent non-Hodgkin's lymphoma

Leuk Res Rep. 2021 Oct 24;16:100275. doi: 10.1016/j.lrr.2021.100275. eCollection 2021.ABSTRACTMonoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mAb, was the first immunotherapy ever used in cancer, and a current cornerstone of lymphoma therapies. Since, we saw development of humanized antibodies, next generations anti-CD20, mAbs targeting other markers on tumor cells (CD19 and CD22), its microenvironment (PD-1, CD47), antibody drug conjugates and bispecific T cell engagers. Given their activity, safety and specificity, mAbs are well poised to remain an essential therapeutic tool for iNHL and other malignancies.PMID:34765437 | PMC:PMC8569585 | DOI:10.1016/j.lrr.2021.100275
Source: Cell Research - Category: Cytology Authors: Source Type: research